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atrial fibrillation
ABSTRACT
Background: Disturbances in atrial microcirculation is recognized as a risk factor for atrial fibrillation (AF). 
AIM: The aim of this study was to determine the associations between circulating soluble vascular cell 
adhesion molecule-1 (sVCAM-1) and the risk of AF and a one-year prognosis among consecutive inpatients. 
Methods: Eighty consecutive inpatients hospitalized due to non-valvular AF and 80 consecutive inpatients 
admitted for exacerbation of chronic coronary syndrome (control group) were enrolled in the study. A cardi-
ologic workup was performed and blood sVCAM-1 concentration was determined using the ELISA method. 
Results: Patients with AF had similar blood sVCAM-1 concentration compared to the control group. AF 
patients treated with new oral anticoagulants (NOACs) were significantly less likely to have a sVCAM-1 
concentration elevated above the median value than patients treated with warfarin (34.2% vs 65.8%; p 
= 0.01). Patients with an increased percentage of fat mass (FM) had lower sVCAM-1 concentration. The risk 
of all-cause mortality and MACE during follow-up rose in individuals with elevated sVCAM-1 (≥ 1242 and 
≥ 587 ng/ml, respectively) with (OR; 95%CI): 5.39; 1.57-18.45; p = 0.007, and 6.00; 1.18-30.37; p = 0.03, 
respectively. Risk of death rose with increase in the ratio of sVCAM-1 and FM (1.02; 1.00-1.04; p = 0.019). 
Conclusions: Elevated sVCAM-1 was associated with all-cause mortality and MACE during one-year fol-
low-up, but do not links the risk of AF. Use of NOACs may favorable affect endothelial function, A lower level 
of sVCAM-1 in obese patients may mediate the phenomenon of the “obesity paradox” in patients with AF. 
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Introduction
Atrial fibrillation (AF) is one of the most prevalent 
forms of cardiac arrhythmia [1]. AF can occur in pa-
tients with cardiovascular disorders, such as coronary 
artery disease, hypertension and valvular heart dis-
ease, and those with extra-cardiac disturbances, thy-
rotoxicosis and dyselectrolytemia, for example. These 
disturbances can affect many pathomechanisms, 
leading to AF. One of the AF substrates is local het-
erogeneity of refractions in atrial muscle cells, cardiac 
pacemakers and the conduction system, which may 
be caused by ischemia. In turn, myocardial ischemia 
may result from an imbalance in the blood supply 
through coronary arteries and/or oxygen demand 
[1]. One potential cause of this type of disturbance is 
endothelial dysfunction [2]. 
Endothelial dysfunction is a risk factor for several 
cardiovascular disorders [3, 4]. This type of disturbance 
reduces the reserve of vascular dilatation, facilitates arte-
rial thrombosis and promotes migration and proliferation 
of vascular wall cells [3, 4]. The most prevalent cause 
of endothelial dysfunction is an inadequate or delayed 
modification of atherosclerosis risk factors (e.g. smok-
ing, hypertension, diabetes and hyperlipidemia). There 
are many markers of global endothelial dysfunction. 
These markers can be invasive, such as intra-arterial 
application of acetylcholine and/or nitroglycerin during 
coronarography, or non-invasive, such as e.g. brachial 
artery flow-mediated dilatation or tonometry of peripheral 
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arteries (digital pulse amplitude tonometry [PAT]). Of the 
biochemical markers of endothelial dysfunction, the one 
most prevalently used is blood concentration of endo-
thelin-1 and adhesion molecules, e.g. E-selectin, P-se-
lectin, intercellular adhesion molecule-1 (ICAM-1), and 
soluble vascular cell adhesion molecule-1 (sVCAM-1) 
[3]. Soluble VCAM-1 is also recognized as a biomarker 
of inflammation [5] and endothelial activation [2]. 
The role of endothelial dysfunction in patients with 
atrial fibrillation remains understudied [3–7]. However, 
it has been reported that the combined dysfunction of 
cardiac (i.e. endocardial, microvascular and coronary) 
and vascular endothelial cells may affect atrial and ven-
tricular cardiomyocyte contractility and remodelling and 
lead to fibrosis. Endothelial dysfunction may also lead 
to reduced synthesis of substances with antithrombotic, 
anti-inflammatory and anti-proliferative properties, such 
as tissue plasminogen activator and nitric oxide (due, 
i.a., to an increased level of the amino acid asymmetric 
dimethylarginine [ADMA], an endogenous inhibitor 
of NO synthase [eNOS]) [7], as well as to increased 
secretion of procoagulant factors, e.g. von Willebrand 
factor (VWF) [7], overexpression of adhesion molecules 
(e.g. sVCAM, sICAM, P-selectin and E-selectin) [5], and 
increase of growth factors (e.g. fibroblast growth factor 
[bFGF] and vascular endothelial growth factor [VEGF]) 
[3]. Through the pathomechanisms mentioned, endo-
cardial and vascular endothelial dysfunction may take 
part in the pathogenesis of AF occurrence, recurrence 
of arrhythmia, the formation of permanent forms of AF, 
and risk of thromboembolic complications [3–8]. 
On the basis of the premises mentioned above, we 
formulated the hypothesis that blood sVCAM-1 con-
centration could, as a biomarker of altered systemic 
endothelial function, indicate the risk of heart atria 
ischemia and cardiac arrhythmia induced by the 
dispersion of the refraction time [3]. As endothelial 
function and angiogenesis are both related to AF risk 
and body mass and composition [9], we assumed that 
endothelial dysfunction may operate as a link between 
the risk of AF and obesity [10, 11]. The aim of this study 
was to determine the associations between circulating 
sVCAM-1 and the risk of AF, type of arrhythmia, risk of 
thromboembolic and hemorrhagic complications and 
one-year prognosis among consecutive inpatients. The 
other purpose of this study was to estimate the role of 
sVCAM-1 as a link between the risk of AF and obesity. 
Patients and methods
Patients
This cohort study was performed with 80 consecu-
tive patients hospitalized due to non- valvular AF and 
a control group containing 80 consecutive inpatients 
hospitalized as a result of exacerbation of chronic coro-
nary syndrome. All the study participants were admitted 
to the same clinic in an urban university hospital. The 
exclusion criteria were as follows: valvular heart disease; 
history or clinical signs of inflammatory processes or 
neoplasm; and lack of informed consent for participa-
tion in the study. Patients were recruited to the study 
between July 1, 2015, and December 31, 2016. 
Medical history was obtained during the first day of 
hospitalization. A physical examination, laboratory tests, 
ECG and transthoracic echocardiography were also 
performed for every patient. After one year, a follow-up 
telephone interview was conducted with the patient or 
his or her relatives. Charlson Comorbidity Index (CCI) 
was scored in every patient. 
Parameters of nutritional status assessment
Due to known associations between VCAM-1 and 
obesity, a nutritional status assessment was performed 
for all 160 study participants. The following parame-
ters were measured: height (cm), body weight (kg), 
waist circumference (WC, cm), and hip circumference 
(HC, cm). Body composition was determined using 
bioelectrical impedance analysis (BIA) and a TANITA 
BC 420 MA device (TANITA Corporation, Japan). Each 
patient underwent a BIA examination between 7 am and 
8 am, on an empty stomach and after urinating. The 
following BIA parameters were analyzed: FM (%, kg), 
VAT score (in the range 1–59), fat-free mass (FFM, kg), 
and skeletal muscle mass (SMM, kg). 
The following secondary parameters were calculat-
ed based on the above-mentioned indices: 
 — body mass index (BMI) (kg/m2): calculated as the 
quotient of body mass expressed in kg and squared 
height expressed in m; 
 — waist-to-hip ratio (WHR): calculated as the quotient 
of waist and hip circumferences (cm); the cut-off val-
ue for the diagnosis of the abdominal distribution of 
adipose tissue was 0.8 for females and 1.0 for males; 
 — waist-to-height ratio (WHtR): calculated as 100 x the 
quotient of waist circumference (cm) and height (cm); 
 — Body Shape Index (ABSI) = WC / [(BMI2/3) 
x (height1/2)]
 — Body adiposity index (BAI) = (HC / height1,5) - 18
Biochemical and sVCAM-1 determinations 
Blood samples were taken from the ulnar vein of 
each patient between 7 am and 8 am on the day of 
admission while he or she was in a fasting state. Rou-
tine determinations were performed in an accredited 
laboratory at the university hospital and blood samples 
were taken to measure sVCAM-1 were centrifuged at 
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4°C and 3600 rev/min. The serum obtained was stored 
at -80 °C until required. sVCAM-1 (CD106) determina-
tion was performed using a commercially available 
enzyme-linked immunosorbent assay (ELISA) kit from 
the Biotech group (cat. no. 850.580.192) in accordance 
with the manufacturer’s instructions.
Blood sVCAM-1 concentration was analyzed as 
a crude value and as a ratio to the following: blood 
C-reactive protein (CRP) concentration, fat mass (FM), 
and visceral adipose tissue (VAT). The rationale for such 
indexation of sVCAM-1 was that its secretion and serum 
concentration are related to the presence of inflammation 
(CRP, inflammation related to obesity and fat mass) [12], 
obesity and body composition (FM, VAT) [9, 13–19]. In 
this way, we can compare sVCAM-1 level adjusted to in-
terpersonal diversity in inflammatory and adiposity status. 
Parameters of transthoracic echocardiography
Transthoracic echocardiography was performed on 
admission for all the study participants by the same, 
experienced cardiologist using an Aplio transthoracic 
ultrasound device (TOSHIBA, Canon Medical Systems, 
USA) and a 2-5 MHz radial probe. The following echo-
cardiographic parameters were determined: interven-
tricular septum thickness (IVST) at end-diastole; poste-
rior wall thickness (PWT); left ventricular end-diastolic 
dimension (LVEDD); maximal wall thickness (MWT), 
relative wall thickness (RWT); left ventricular ejection 
fraction (LVEF); left ventricular mass (LVM); and left atri-
um diameter indexed to body surface area (LAD/ BSA), 
left atrium area indexed to BSA (LAA/ BSA) and left 
atrium volume in apical four-chamber view indexed to 
BSA (LAV/ BSA). LVEF was assessed using the biplane, 
two-dimensional method of disks (modified Simpson’s 
rule) in apical four- and two-chamber views. Left ventric-
ular mass was calculated using the following formula: 
LVM (g) = 0.8 × {1.04 × [([LVEDD + IVST + PWT]3 
- LVEDD3)]} + 0.6. Body surface area was calculated 
using the following formula: 
BSA (m2) = 0.01666667 × height 0.5 × body mass 0.5
Measured outcomes
For at least one year following discharge (medi-
an ± interquartile range; 406; 374-442 days), the follow-
ing outcomes were assessed measured by the same 
physician for each patient in the AF and control groups 
during a telephone interview with the patient or his or her 
relatives: all-cause mortality, all-cause readmission (e.g. 
due to acute coronary syndrome, cardiac heart failure 
exacerbation, arrhythmia recurrence) and stroke occur-
rence. The occurrence of composite end-point (major 
adverse cardiac event, MACE) was also analyzed and 
defined as the occurrence of any outcome measured 
(i.e. death or all-cause readmission or stroke). 
The secondary outcomes comprised the above-de-
termined parameters obtained during hospitalization 
both for patients with AF and those in the control group. 
Bioethics
The investigation was conducted in compliance with 
the Declaration of Helsinki for medical research, after 
receiving permission from local Bioethical Committee 
No. 389/2015. Each patient gave written consent to 
participate in the study. 
Statistics
Statistical analysis was conducted using a licensed 
version of statistical software STATISTICA version 
13.1 (a data analysis software system) developed by Stat-
Soft, Inc. (2017). The statistical significance level was set 
at a p-value < 0.05. The normal distribution of the study 
variables was checked using the Shapiro-Wilk test. The 
results were mainly presented as the mean ± standard 
deviation, or n, %. The statistical significance of differenc-
es between groups was verified using the Student’s t-test, 
the Mann-Whitney U test and the Chi2 test. Spearman’s 
correlations were checked to determine the relationships 
between sVCAM-1 and the clinical, biochemical and 
echocardiographic parameters. Survival analysis was 
performed by plotting the Kaplan-Meier curves for two 
probes and F Cox test for determination of statistical 
significance between them. Cut-off values for crude and 
indexed values of sVCAM-1 that have a predictive value 
for the risk of AF and the measured outcomes were 
determined for maximal Youden’s indices by plotting 
the receiver operator curves (ROC). All the patients 
were then classified into two groups based on those 
cut-off values. For the qualitative variables obtained, the 
odds ratio (OR) was determined (using the free internet 
calculator available at https://www.medcalc.org/calc/ 
/odds_ratio.php) as the risk that AF would occur with an 
associated higher value of sVCAM-1, compared to the 
chance of AF occurring in patients with a lower value. 
The relationships between blood sVCAM-1 concentration 
and risk of AF and the measured outcomes were also 
verified using the logistic regression method. 
Results
Clinical characteristics
Compared to individuals in the control group, 
patients with AF were less prevalently smokers, were 
less likely to have a history of myocardial infarction, 
and tended to have a lower score on the CCI and 
HAS-BLED, as well as lower percentage of SMM. 
Moreover, they were more likely to have a higher 
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Table 1. Comparison of clinical characteristics between the two groups studied






Age (years) 69.62 ± 8.90 69.18 ± 8.44 0.746
Male gender (n, %) 41 (51.25%) 42 (52.50%) 0.940
Smoking habit (n, %) 39 (48.75%) 65 (81.25%) < 0.001
Hypertension (n, %) 68 (85.00%) 65 (81.25%) 0.636
Diabetes mellitus (n, %) 29 (36.25%) 34 (42.50%) 0.385
HAS-BLED score 1.2 ± 0.89 1.9 ± 0.95 < 0.001
CHA2DS2VASc score 3.35 ± 1.54 -
Past myocardial infarction (n, %) 9 (11.25%) 20 (25.00%) 0.022
CABG (n, %) 3 (3.75%) 9 (11.25%) 0.069
CCI score 4.09 ± 1.76 4.94 ± 1.96 0.004
BMI (kg/m2) 31.27 ± 6.08 27.04 ± 4.77 < 0.001
WHR 0.99 ± 0.09 0.98 ± 0.09 0.677
WHtR 0.68 ± 0.47 0.43 ± 0.50 0.001
ABSI 0.085 ± 0.005 0.087 ± 0.006 0.038
BAI 32.74 ± 7.38 29.84 ± 6.11 0.008
MNA score 25.10 ± 2.95 23.89 ± 3.18 0.014
FM in BIA (%) 35.87 ± 9.49 29.91 ± 9.08 < 0.001
Obesity diagnosis (25% FM for males; 35% FM for 
females)
53 (66.25%) 35 (43.75%) 0.007
FM (kg) 32.29 ± 12.30 22.63 ± 9.42 < 0.001
VAT score 15.46 ± 4.89 12.10 ± 3.87 < 0.001
Measured outcomes during 420.82 ± 56.58 days of follow-up
Death (n, %) 8 (10.00%) 5 (6.25%) 0.402
Stroke (n, %) 2 (2.5%) 2 (2.5%) 0.978
Myocardial infarction (n, %) 0 2 0.160
Readmission (n, %) 35 (43.75%) 47 (58.75%) 0.087
MACE (n, %) 44 (55.00%) 51 (63.75%) 0.219
ABSI — A body shape index; BAI — body adiposity index; BIA — bioelectrical impedance analysis; BMI — body mass index; CABG — coronary 
artery bypass graft; CCI — Charlson Comorbidity Index; CHA2DS2VASc — evaluates stroke risk in patients with AF; FM — fat mass (expressed 
as kg, and a % of the whole body mass); FFM — fat-free mass; HAS-BLED — a scoring system for estimating bleeding risk in patients with AF; 
MACE — major adverse cardiovascular event combined with death, stroke, and all-cause rehospitalization; MNA — minimal nutritional assess-
ment; VAT — visceral adipose tissue; WHR, waist-to-hip ratio; WHtR — waist-to-height ratio
MNA score, higher BMI, a higher percentage of fat 
mass and greater indices of visceral fat distribution 
(WHtR, ABSI, BAI, VAT score) (Tab. 1). Patients with 
AF were also more likely to have lower values of 
LDL and higher blood concentrations of NH(2)-ter-
minal pro-brain natriuretic peptide (NT-proBNP) 
and hemoglobin (Tab. 2). The heart chambers of 
patients with AF also had thicker heart walls (IVST, 
PWT, MWT), larger dimensions of heart chambers 
(LVEDD, LAD/BSA, LAA/BSA, LAV/BSA) and a lower 
LVEF (Tab. 2). 
sVCAM-1 and parameters measured in patients 
with AF
Patients with AF did not differ from the control 
group in relation to serum sVCAM-1 concentration, 
although the sVCAM-1-to-CRP ratio was lower in 
patients with AF than in the control group (Tab. 2). 
Subgroups of patients with AF divided in relation to 
the type of arrhythmia experienced did not differ in 
relation to blood sVCAM-1 concentration either. The 
respective values of sVCAM-1 for patients with par-
oxysmal, persistent and permanent AF amounted to: 
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Table 2. sVCAM-1, biochemical determinations and echocardiographic parameters for the two groups studied






sVCAM-1 (ng/ml) 1264.14 ± 620.95 1241.18 ± 593.56 0.812
sVCAM-1/CRP (ng/mg) 613.32 ± 677.39 964.52 ± 1301.25 0.035
sVCAM-1/FM (ng/ml/%) 39.12 ± 25.66 45.50 ± 26.10 0.117
sVCAM-1/VAT (ng/ml/score) 94.15 ± 64.94 113.54 ± 68.60 0.070
Hemoglobin (g/L) 136.00 ± 14.70 130.90 ± 16.40 0.039
LDL cholesterol (mg/dl) 88.28 ± 37.27 101.29 ± 41.24 0.039
Triglycerides (mg/dl) 110.70 ± 49.80 122.78 ± 78.30 0.249
Creatinine (mg/dl) 1.04 ± 0.35 0.98 ± 0.48 0.401
CRP (mg/dl) 12.94± 30.45 7.91 ± 13.82 0.183
NT-proBNP (ng/ml) 2107.88 ± 3040.70 944.51 ± 1854.53 0.004
Interventricular septum (mm) 12.02 ± 1.83 11.25 ± 1.84 0.009
Posterior wall thickness (mm) 11.81 ± 1.72 10.82 ± 1.92 0.001
Maximal wall thickness (mm) 11.92 ± 1.74 11.03 ± 1.83 0.002
Relative wall thickness (mm) 0.48 ± 0.11 0.52 ± 0.48 0.497
Left ventricular mass /BSA (g/m2) 120.71 ± 34.38 107.29 ± 32.24 < 0.001
LVEF (%) 53.12 ± 10.14 58.68 ± 12.01 0.002
LVEDD (mm) 50.73 ± 7.35 47.75 ± 8.40 0.019
Left atrium volume in apical four-chamber view indexed to BSA (ml/
m2)
53.07 ± 19.34 38.68 ± 12.36 < 0.001
Left atrium diameter indexed to BSA (mm/m2) 23.07 ± 4.88 21.87 ± 3.09 0.068
Left atrium area in apical four-chamber view indexed to BSA (cm2/m2) 13.43 ± 3.10 10.91 ± 2.20 < 0.001
BSA — body surface area (m2); CRP — C-reactive protein; FM — fat mass (expressed as a % of whole body mass); LDL — low-density lipo-
protein; LVEDD — left ventricular end-diastolic dimension; LVEF — left ventricular ejection fraction; NT-proBNP — NH(2)-terminal pro-brain 
natriuretic peptide; SMI — skeletal muscle mass index; sVCAM-1 — soluble vascular cell adhesion molecule-1; VAT — visceral adipose tissue. 
Conversion factors to SI units are as follows: for LDL cholesterol — 0.0259 [mmol/l]; triglycerides — 0.0113 [mmol/l]; creatinine — 88.4 [mcmol/l]
1238.73 ± 620.61 ng/ml; 1219.64 ± 527.11 ng/ml; 
and 1396.23 ± 816.53 ng/ml. 
The associations between blood sVCAM-1 con-
centration and clinical factors were analyzed both in 
split analysis in subgroups of AF patients divided in 
relation to the median blood sVCAM-1 concentration 
(< and ≥ 1139 ng/ml) and using non-parametric Spear-
man’s correlations. 
Patients with AF and blood sVCAM-1 concentration 
above the median value (n = 40) in comparison with 
patients with a blood sVCAM-1 concentration below the 
median value (n = 40): 
 — were treated significantly less often with new direct 
oral anticoagulants (NOACs: 37.50% vs 62.50%; 
p = 0.01), and patients treated with NOACs (n = 38, 
47.50%) were significantly less likely to have elevat-
ed blood sVCAM-1 concentration (34.2% vs 65.8%; 
p = 0.01); 
 — were treated more prevalently with warfarin (62.50% 
vs 37.50%; p = 0.01);
 — had lower minimal nutritional assessment (MNA) 
total score (24.26 ± 2.69 vs 25.92 ± 2.99 score; 
p = 0.011);
 — had a lower VAT level  (14.25 ± 4.65 vs 
16.68 ± 4.89 score; p = 0.026); and
 — had a lower left ventricular mass (228.18 ± 58.81 vs 
266.81 ± 96.16 g; p = 0.033).
Moreover, AF patients with obesity (percentage FM 
for males > 25% and an for females > 35%) compared 
to AF patients with lower percentage of FM, had, i.a. 
lower sVCAM-1 concentration indexed to percentage of 
FM (34.28 ± 20.15 vs 48.30 ± 32.45; p = 0.020), lower 
LVM (232.01 ± 69.45 vs 269.72 ± 83.4 g; p = 0.018), 
and lower LVM/BSA (LVMI; 116.84 ± 31.17 vs 
131.03 ± 37.43; p = 0.045).
For both groups of patients, blood sVCAM-1 concen-
tration correlated with the HAS-BLED score (R = 0.19; 
p = 0.017), New York Heart Association (NYHA) class 
(R = 0.23; p = 0.004), CCI (R = 0.26; p = 0.001), Nutri-
tional Risk Screening 2002 (NRS-2002) score (R = 0.28; 
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p < 0.001), CRP (R = 0.20; p = 0.013), NT-proBNP 
(R = 0.26; p < 0.001); MNA score (R = -0.34, p < 0.001); 
and blood albumin concentration (R = -0.26; p = 0.001). 
Moreover, for both groups of patients, we identified only 
one statistically significant correlation: that between 
sVCAM-1 and LAD/BSA (R = 0.19; p = 0.02). 
Among patients with AF, we found no significant 
correlations between sVCAM-1 and echocardiographic 
parameter values, or CHA2DS2VASc and HAS-BLED 
scores, which evaluates thromboembolic and hemor-
rhagic risk in patients with AF, respectively. However, 
these patients presented significant correlations be-
tween sVCAM-1 and parameters of BIA, such as FFM 
(R = -0.23; p = 0.037), SMM (R = -0.22; p = 0.048), and 
VAT score (R = -0.27; p = 0.014). In patients with AF, the 
relationships between sVCAM-1 and CCI, NRS-2002, 
MNA, blood albumin and CRP concentrations were 
statistically significant and had similar power like that for 
both groups of patients (data not presented in detail). 
sVCAM-1 and the measured outcomes
During, on average, 420.82 ± 56.58 days of fol-
low-up, the prevalence of outcomes measured did 
not differ significantly between the two study groups 
(Tab. 1). Compared to patients who died during the 
follow-up (n = 13, 8.13%), the individuals who survived 
for the whole of the observation period (n = 147) were 
statistically significantly younger, had higher body 
weight and nutritional scores (MNA, NRS-2002), lower 
blood NT-pro-BNP concentration, higher BIA param-
eters, lower LAD/BSA (detailed data not presented), 
and borderline lower serum sVCAM-1 concentration 
(1228.66 ± 598.23 vs 1523.15 ± 647.74 ng/ml; 
p = 0.093). 
Eight of the 80 patients with AF (10.0%) died 
during the observation period. These patients had 
only slightly higher serum sVCAM-1 concentration 
(1397.86 ± 721.88 vs 1249.29 ± 612.71 ng/ml; p = 0.52) 
in comparison with AF patients who survived. Similar 
differences concerned patients with paroxysmal atrial 
fibrillation and arrhythmia recurrence, patients who 
required readmission or who had a stroke or myocar-
dial infarction during the observation period (data not 
presented in detail). 
For survival analysis, the cut-off value for sV-
CAM-1 was obtained in ROC analysis with the lowest 
Youden’s index for the risk of all- cause mortality 
during follow-up (sVCAM-1 < and ≥ 1242.40 ng/ml; 
the area under the curve (AUC) and 95% confidence 
interval (CI): 0.664; 0.507-0.0.820; p = 0.040; Fig. 
1), and for the risk of MACE during follow-up (sV-
CAM-1 < and ≥ 586.60 ng/ml; AUC; 95%CI: 0.594; 
0.501-0.687; p = 0.049). The Kaplan- Meier analysis 
showed that patients with higher sVCAM-1 had worse 
long term survival than their counterpart and the curves 
began to divide after 350 days after discharge (Fig. 2). 
The risk of all-cause mortality during follow-up for 
individuals with higher sVCAM-1 in whole patients 
group amounted to (OR; 95%CI): 5.39; 1.57-18.45; 
p = 0.007. Of all studied patients and patients with AF, 
those who had higher sVCAM-1 concentration had 
also a higher risk of MACE (Fig. 3), with OR; 95% CI 
amounted to 6.00; 1.18-30.37; p = 0.03. We obtained 
also statistically significant logistic regression model 
for relationships between all- cause mortality during 
follow-up and blood sVCAM-1 concentration indexed to 
percentage of fat mass with OR, 95%CI per unit: 1.02; 
1.00-1.04; p = 0.019. 
Discussion
In this study, we tested the hypothesis of whether 
endothelial dysfunction, diagnosed on the basis of 
increased blood sVCAM-1 concentration, affects AF 
occurrence and patient prognosis (risk of all-cause 
mortality, readmission, or stroke). We did so because 
endothelial dysfunction is related to the risk of sev-
eral cardiovascular diseases [3], to the presence of 
inflammation [12], to obesity and body composition 
[9, 13–19], as well as being involved in the risk of 
thromboembolic complications of AF [20–24]. We also 
investigated whether sVCAM-1 might link obesity with 
the pathogenesis of AF and patient prognosis [10, 11]. 
sVCAM-1 and AF occurrence and patient 
prognosis
In our study we confirmed the positive associations 
between abdominal obesity and risk of AF (Tab. 1) [10, 
11], however, we did not corroborate the hypothesis 
that endothelial dysfunction, expressed by elevated 
sVCAM-1 is associated the risk of AF (Tab. 2), the 
risk of thromboembolic and hemorrhagic complica-
tions, expressed by CHA2DS2VASc and HAS-BLED 
scores. Therefore, our results did not corroborate the 
work summarized by Smiljic [3] and Wijesurendra and 
Casadei [4], who showed associations between an 
increased risk of AF and elevated levels of endothelial 
dysfunction biomarkers. Based on the 909 participants 
of the Bruneck Study, Willeit et al. [5] found higher blood 
sVCAM-1 concentration to be a predictor of new-onset 
AF in the general community. Moreover, in studies by 
Verdejo et al. [6] and Harling et al. [2], an increased 
blood sVCAM-1 concentration was a biomarker of 
AF occurrence after coronary artery bypass grafting 
(CABG). Associations between sVCAM-1 and AF occur-
rence were also reported by other authors [24–31]. In 
a study by Zhang et al. [32], blood sVCAM-1 concen-
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nificant increase in the risk of all-cause mortality in the 
whole study group. Moreover, serum sVCAM-1 concen-
tration ≥ 584 ng/ml linked higher MACE risk both in the 
whole study group, in AF patients group since 350 days 
after discharge (Fig. 3), and patients with exacerbation 
of chronic coronary syndromes. These data corroborate 
with reports showing on association between all-cause 
and cardiovascular mortality of patients with various 
cardiovascular disorders and endothelial dysfunction 
[3, 31] and elevated sVCAM-1 [5]. 
sVCAM-1 and cardiovascular disease 
advancement and the risk of thromboembolic and 
hemorrhagic complications
Breitenstein et al. [20] showed that, in isolated and 
cultured endocardial human cells of patients with AF, 
the endocardium of the left atrium had a higher expres-
sion of prothrombotic and pro-inflammatory markers, 
including sVCAM-1, than the endocardium of the right 
atrium. The role of blood prothrombotic state as a risk 
factor for thromboembolic complications in patients 
with AF was also described in analyses by Weymann 
et al. [31] and Polovina et al. [33]. However, Ruediger 
et al. [8] did not confirm the role of endothelial function 
as a marker for the difference in thromboembolic risk 
among Caucasian and Indian patients with AF. In our 
study, we found only weak positive Spearman correla-
tions between sVCAM-1 and NYHA class, CCI score, 
blood NT-proBNP concentration, and left atrium size. 
Moreover, among patients with AF, we did not find 
significant correlations between sVCAM-1 and values 
of echocardiographic parameters or CHA2DS2VASc. 
These discrepancies are difficult to explain. 
However, we did find relationships between HAS-
BLED score (for the whole study group) and the type of 
Figure 2. Risk of all-cause mortality in relation to 
sVCAM-1 concentration in Kaplan-Meier analysis for all 
study patients 
Figure 1. ROC curve for prediction of all-cause mortality 
by sVCAM-1 in both study groups
tration was higher than in healthy controls, although this 
adhesion molecule lost its significance as a predictor of 
AF in multifactorial analysis. Seljeflot et al. [7] found im-
paired endothelial function, expressed by higher blood 
vWF and ADMA concentrations, in patients with AF who 
were over the age of 75 compared to an age-matched 
control group with sinus rhythm. However, similar to 
our results (Tab. 2), blood sVCAM-1 concentration was 
not higher to a statistically significant extent in the AF 
patients in their study. 
Moreover, we found that elevated sVCAM-1 (Fig. 1, 
2) and increase sVCAM-1 indexed to the percentage 
of FM (logistic regression) were associated with a sig-
Figure 3. Risk of a major adverse cardiovascular event 
(MACE) in relation to sVCAM-1 concentration in Kaplan-
Meier analysis for AF patients
Marzena Anaszewicz et al., Soluble vascular cell adhesion molecule-1 in patients with non-valvular atrial fibrillation
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anticoagulant taken before the study (in the AF group). 
The HAS-BLED score correlated positively with blood 
sVCAM-1 concentration for the whole study group, and 
patients with AF whose blood sVCAM-1 concentration 
was above the median value took NOACs significantly 
less often than their counterparts. The first observation 
can be interpreted as an aggregate effect of different 
factors (e.g. hypertension, older age and renal insuffi-
ciency) inducing endothelial damage, and the second 
may be explained by the protective and reparative 
properties of rivaroxaban mediated by modification 
of urokinase plasminogen activator and matrix metal-
lopeptidase-2 expression, as well as by the inhibiting 
pro-inflammatory effects of factor Xa [34, 35]. However, 
our patients took two different NOACs (dabigatran and 
rivaroxaban) and the small sample size made it impos-
sible to analyze differences between the two drugs. 
sVCAM-1 and patient nutritional status and body 
composition
The risk of AF showed a U-shaped relation to body 
mass [10]. One of the explanations for this relationship 
is the cardiac and vascular effect of adipocytokines [9, 
10, 11, 13–17, 19, 30–37]. It was reported that visfatin 
may induce expression of ICAM-1 and VCAM-1 and, in 
turn, leukocyte adhesion to endothelial cells and aortic 
endothelium [37]. In our study, blood sVCAM-1 con-
centration correlated negatively with the parameters 
of patient nutritional status (MNA and NRS-2002), and 
skeletal muscle mass (in BIA). Moreover, patients with 
AF had lower sVCAM-1 indexed to FM and VAT (Tab. 
2), and AF patients with the increased percentage of 
FM had lower sVCAM-1, lower LVM and LVMI. Because 
of elevated sVCAM-1 in our study increased the risk of 
all-cause mortality by than five times and dysregulation 
in adipocytokines and endothelial injury markers are 
typical for obese patients [19, 36], this may suggest 
a protective effect of obesity on the risk of AF; part of 
what might be regarded as the “obesity paradox” [10]. 
The hypothesis is also supported by evidence of an 
increase in the percentage of fat mass reducing the 
value of the sVCAM-1-to-FM ratio, a rise that was slightly 
associated with the risk of all-cause mortality in logistic 
regression analysis. 
Strengths and limitations of the study 
The first potential strength of our study is its sample 
size, which was similar to or greater than those in the 
majority of the works cited [2, 6, 32]. Moreover, our 
study group consisted of consecutive, non-selected 
inpatients, which supports the assertion that our study 
was performed in a real-world population. The second 
strength of our study is the matching of the control 
group in relation to age and gender, which helps reduce 
the effect of a patient’s age on systemic endothelial 
function. The main study limitation was that there were 
some differences in the clinical characteristics of the two 
groups studied (Tab. 1), particularly in relation to CCI, 
which, due to the above-mentioned pathophysiological 
relations, might be an explanation for it not being pos-
sible to find a higher blood sVCAM-1 level in patients 
with AF compared to the control group (Tab. 2).
Conclusions
Elevated serum sVCAM-1 concentration was associa - 
ted with the risk of all-cause mortality and MACE, but 
did not link the risk of AF and thromboembolic compli-
cations. The use of new oral anticoagulants in patients 
with AF may exert a favorable effect on endothelial 
function and be associated with lower sVCAM-1 serum 
concentration. A lower sVCAM-1 level in obese patients 
and decrease in risk of all-cause mortality with per 
unit increase of sVCAM-1 to FM ratio suggest that the 
“obesity paradox” that exists in patients with AF may 
be mediated by a lower level of endothelium damage 
markers. 
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